Senseonics
Senseonics' revenue rose 56.9% to $35 million in fiscal 2025. Its operating margin was −193.8%, up from −333.1% a year earlier. Free cash flow was −$60 million. The diluted share count rose 32.5%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Senseonics does
Senseonics is a medical technology company that makes Eversense, a continuous glucose monitoring (CGM) system for people with diabetes. A small sensor is placed under the skin and measures glucose, a removable transmitter sends the readings to an app, and the app shows real-time glucose data. The Eversense 365 sensor lasts up to twelve months, and the Eversense E3 sensor lasts six months. Senseonics says this compares with seven to 15 days for CGM systems worn on the skin.
Revenue comes from selling Eversense products. Until the end of 2025, its partner Ascensia Diabetes Care had the exclusive right to distribute Eversense worldwide. On December 31, 2025, the two companies signed agreements to move commercial operations back to Senseonics. In January 2026 Senseonics began marketing and distributing Eversense 365 in the United States with its own sales force. Effective January 1, 2026, it is entitled to 100% of the revenue from Eversense sales in Italy, Germany, Spain and Sweden. It expects to launch Eversense 365 in Europe by the second half of 2026.
The company describes itself as in the early stages of commercializing the Eversense brand. It competes with other makers of glucose monitors. As of December 31, 2025, it had 137 full-time employees, and it expects that number to grow as it takes on selling its own products.
Its biggest risks, as it describes them
- It has lost money since it began, and says there is substantial doubt it can keep operating as a going concern.
- It may not successfully take commercial responsibility for Eversense back from Ascensia and expand sales in the U.S. and Europe.
- It competes with larger glucose monitoring makers, and insurers may not cover or fully pay for Eversense.
- It must build a broad network of providers who insert and remove its implanted sensor.
- It relies on third parties to make Eversense, so supplier problems could hurt its results.
Income statement
Senseonics lost money in fiscal 2025: a net loss of $69 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 182 | 156 | 110 | 75 | 94 |
| Debt incl. finance leases | 60 | 56 | 41 | 35 | 36 |
| Net debt (negative means net cash) | −122 | −100 | −68 | −40 | −58 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 1.1x | — | 0.6x |
| Interest coverage | −3.4x | −3.7x | −6.8x | −8.9x | −13.8x |
| Current ratio | 7.8x | 5.1x | 7.5x | 2.4x | 4.8x |
| Quick ratio | 7.5x | 4.9x | 7.0x | 2.2x | 4.5x |
Cash flow
Projections
Project Senseonics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Senseonics says to expect
- Full year 2026: global net revenue and gross margin
Senseonics is raising its full-year 2026 global net revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98%, and is raising its full-year gross margin guidance to more than 60% from its prior range of 58% to 61%.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $627,302 of Senseonics shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 13, 2026 | Douglas A RoederDirector | Bought | 17,041 | $10.32 | $175,860 | Form 4 |
| Aug 19, 2026 | Douglas A RoederDirector | Bought | 13,953 | $8.98 | $125,300 | Form 4 |
| May 12, 2026 | Douglas A RoederDirector | Bought | 22,686 | $5.56 | $126,134 | Form 4 |
| Mar 13, 2026 | Douglas A RoederDirector | Bought | 17,500 | $5.73 | $100,275 | Form 4 |
| Mar 13, 2026 | Timothy T GoodnowPresident and CEO, Director | Bought | 17,225 | $5.79 | $99,733 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 2 of 9 | 4 of 9 |
| Rule of 40 | −278.3% | −278.7% | −114.0% |
| Altman Z'' | −18.25 | −32.56 | −24.07 |
| Accruals ratio | 6.2% | −15.2% | −8.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Pass | Fail | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 2 of 9 | 4 of 9 |
Compare
Put Senseonics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Senseonics | FY25 | 56.9% | −193.8% | −170.9% | — | — | 4 | |
| ClearPoint Neuro | FY25 | 17.8% | −65.4% | −66.1% | −104.7% | — | 4 | Compare |
| CytoSorbents | FY25 | 4.1% | −39.8% | −33.8% | — | — | — | Compare |
| Orchestra BioMed | FY25 | 1,169.2% | −154.7% | −147.7% | — | — | 5 | Compare |
| Stereotaxis | FY25 | 20.3% | −68.3% | −42.5% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 6 | 19 | 21 | 5 | 14 | 16 | 22 | 22 | 35 |
| Revenue growth | 773.7% | 1,819.6% | 196.8% | 12.6% | −76.8% | 176.3% | 19.9% | 36.6% | 0.4% | 56.9% |
| Gross profit | −0 | −3 | −8 | −19 | −17 | −1 | 3 | 3 | 0 | 16 |
| Research and development | 26 | 31 | 32 | 38 | 20 | 27 | 40 | 49 | 41 | 32 |
| Operating income | −42 | −56 | −88 | −131 | −79 | −57 | −69 | −76 | −75 | −68 |
| Net income | −44 | −59 | −94 | −116 | −175 | −302 | 142 | −60 | −79 | −69 |
| Diluted EPS (US$) | −9.80 | −10.20 | −12.00 | −12.20 | −15.40 | −14.40 | −2.20 | −2.20 | −2.50 | −1.66 |
| Diluted shares (millions) | 4 | 6 | 8 | 9 | 11 | 21 | 31 | 28 | 32 | 42 |
| Cash flow | ||||||||||
| Cash from operations | −38 | −56 | −91 | −136 | −67 | −56 | −66 | −70 | −60 | −59 |
| Capital expenditure | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 2 | 1 |
| Free cash flow | −38 | −56 | −92 | −137 | −68 | −56 | −67 | −71 | −63 | −60 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 2 | 4 | 6 | 8 | 7 | 9 | 9 | 9 | 9 | 10 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 20 | 36 | 137 | 96 | 18 | 182 | 156 | 110 | 75 | 94 |
| Debt incl. finance leases | 19 | 24 | 15 | 12 | 57 | 60 | 56 | 41 | 35 | 36 |
| Total assets | 22 | 46 | 160 | 133 | 36 | 199 | 178 | 138 | 100 | 126 |
| Total liabilities | 27 | 39 | 89 | 141 | 177 | 384 | 143 | 65 | 79 | 65 |
| Shareholders' equity | −5 | 7 | 71 | −9 | −144 | −186 | −3 | 36 | −17 | 61 |
| Margins and ratios | ||||||||||
| Gross margin | −98.8% | −53.1% | −43.1% | −91.3% | −350.9% | −5.9% | 16.6% | 13.8% | 2.4% | 44.7% |
| Operating margin | −12,781.0% | −883.6% | −463.1% | −613.4% | −1,598.9% | −418.1% | −418.7% | −337.7% | −333.1% | −193.8% |
| Net margin | −13,231.9% | −927.4% | −496.9% | −542.5% | −3,539.5% | −2,211.9% | 867.2% | −269.7% | −349.8% | −196.0% |
| Free cash flow margin | −11,594.9% | −880.0% | −485.2% | −643.6% | −1,366.0% | −411.6% | −406.5% | −314.9% | −279.0% | −170.9% |
| Rule of 40 (growth + FCF margin) | −10,821.2% | 939.5% | −288.4% | −631.0% | −1,442.8% | −235.3% | −386.7% | −278.3% | −278.7% | −114.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −239.3% | −369.1% | — | — | — | −363.6% | −817.2% | −310.7% |
| Return on assets | −317.2% | −173.3% | −91.3% | −78.9% | −207.6% | −257.6% | 75.5% | −38.2% | −65.9% | −61.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |